Also, almost two years after it agreed to buy Lexington-based Dicerna Pharmaceuticals Inc. for $3.3 billion, Novo Nordisk has scored its first drug approval from the acquisition. Here's news from the life sciences you may have missed.
Also, almost two years after it agreed to buy Lexington-based Dicerna Pharmaceuticals Inc. for $3.3 billion, Novo Nordisk has scored its first drug approval from the acquisition. Here's news from the life sciences you may have missed.
